| Source: | Semisynthetic, from
Puromycin |
| Synonyms | |
| Description: | Puromycin Aminonucleoside is a puromycin analog which does not inhibit protein synthesis or induce apoptosis |
| CAS number: | 58-60-6 |
| Merck index: | |
| Molecular weight: | 294.3 |
| Structure: | 
 |
| Molecular Formula: | C12H18N6O3 |
| Canonical SMILES: |
|
Solubility
information: | Water |
| Specifications | |
| Appearance: | White powder |
| Purity: | At least 98% by TLC, HPLC |
| λmax: | |
| Melting point | 218°C-222°C |
| Solubility | Clear colorless solution at 10mg/ml water |
| Storage | +4°C |
| Applications | |
| Warnings | |
| Classification | Nucleoside antibiotic
Protein synthesis inhibitor |
| Related products |
Puromycin
|
| | For Research use only. Not for Human or Drug use
GMP/API grade available on request
No genetically modified organisms are used.
Comment: Puromycin Aminonucleosideis manufactured from Puromycin dihydrochloride . See there for raw materialas from animal origin. |
| Publications | |
| | Moreira-Rodrigues M, Roncon-Albuquerque R Jr, Henriques-Coelho T, Sampaio-Maia B, Leite-Moreira A, Pestana M.
Morphologic, molecular and hemodynamic cardiac alterations in a model of nephropathy induced by puromycin aminonucleoside.
Rev Port Cardiol. 2006 May;25(5):509-18. |
| | Egashira Y, Nagaki S, Sanada H.
Tryptophan-niacin metabolism in rat with puromycin aminonucleoside-induced nephrosis.
Int J Vitam Nutr Res. 2006 Jan;76(1):28-33. |
| | Hagiwara M, Yamagata K, Capaldi RA, Koyama A.
Mitochondrial dysfunction in focal segmental glomerulosclerosis of puromycin aminonucleoside nephrosis.
Kidney Int. 2006 Apr;69(7):1146-52. |
